Abstract
Lymphoplasmacytic lymphoma (LPL) is an uncommon B-cell non-Hodgkin lymphoma in which the affected tissue, usually bone marrow, is infiltrated by small lymphocytes, plasmacytoid lymphocytes, and plasma cells. The lymph nodes, spleen and other tissues/organs in the body are less commonly infiltrated by the neoplastic cells. The clinical course of LPL is indolent although some studies report a more aggressive course and adverse outcomes especially in patients with other primary malignancies including skin cancers. We report an unusual finding of widespread multi-organ involvement by LPL in a 69-year-old male with multiple comorbid conditions and malignant melanoma. He initially presented to the hospital three years ago with hepatosplenomegaly and lymphadenopathy. Pathologic work-up including bone marrow evaluation confirmed the diagnosis of LPL. He was also diagnosed with Waldenström macroglobulinemia.
Highlights
We report an unusual finding of widespread multi-organ involvement by Lymphoplasmacytic lymphoma (LPL) in a 69-year-old male with multiple comorbid conditions and malignant melanoma
Lymphoplasmacytic lymphoma (LPL) is a neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells, commonly involving the bone marrow and sometimes the lymph nodes and spleen, which do not meet the criteria for other small B-cell lymphoid neoplasms with plasmacytic differentiation [1]
We report autopsy findings of widespread involvement of multiple tissues and organs by lymphoma in a 69-year-old male who developed both melanoma and non-melanoma skin cancer in the setting of LPL/Waldenström’s macroglobulinemia
Summary
Lymphoplasmacytic lymphoma (LPL) is a neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells, commonly involving the bone marrow and sometimes the lymph nodes and spleen, which do not meet the criteria for other small B-cell lymphoid neoplasms with plasmacytic differentiation [1]. The diagnosis of LPL is mainly based on histopathologic evaluation of involved tissues, immunophenotypic studies and exclusion of other small B cell lymphoid neoplasms with plasmacytic differentiation. The clinical course of LPL is indolent; some studies report a more aggressive course with poor clinical outcomes [9]. Factors such as advanced age, poor performance status, peripheral blood cytopenias, and high beta-2 microglobulin levels have been associated with poor prognosis in patients with LPL while the presence of increased immunoblasts/transformed cells and deletion 6q are considered independent adverse factors [2]. Patients with NHL have aggressive forms of skin cancer including melanomas and demonstrate worse outcomes including disease recurrence, metastasis and death [10]. LPL may transform to diffuse large B-cell lymphoma and is associated with poor survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pathology and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
